Oxygen microcapsules improve immune checkpoint blockade by ameliorating hypoxia condition in pancreatic ductal adenocarcinoma

被引:19
|
作者
Wu, Jiangchao [1 ,2 ,3 ]
Wang, Xun [1 ,2 ,3 ]
Chen, Li [4 ,5 ,6 ]
Wang, Jianing [1 ,2 ,3 ]
Zhang, Junlei [1 ,2 ,3 ]
Tang, Jianghui [1 ,2 ,3 ]
Ji, Yongtao [1 ,2 ,3 ]
Song, Jinyuan [1 ,2 ,3 ]
Wang, Lin [1 ,2 ,3 ]
Zhao, Yaxing [1 ,2 ,3 ]
Zhang, Hui [1 ,2 ,3 ]
Li, Taohong [1 ,2 ,3 ]
Sheng, Jianpeng [1 ,2 ,3 ]
Chen, Dong [4 ,5 ,6 ]
Zhang, Qi [1 ,2 ,3 ]
Liang, Tingbo [1 ,2 ,3 ]
机构
[1] Zhejiang Univ, Affiliated Hosp 1, Dept Hepatobiliary & Pancreat Surg, Sch Med, Hangzhou 310003, Peoples R China
[2] Zhejiang Univ, Affiliated Hosp 1, Zhejiang Prov Key Lab Pancreat Dis, Sch Med, Hangzhou 310003, Peoples R China
[3] Zhejiang Univ, Canc Ctr, Hangzhou 310003, Peoples R China
[4] Zhejiang Univ, Affiliated Hosp 1, Sch Med, Dept Med Oncol, 79 Qingchun Rd, Hangzhou 310003, Zhejiang, Peoples R China
[5] Zhejiang Univ, Coll Energy Engn, Hangzhou 310027, Peoples R China
[6] Zhejiang Univ, State Key Lab Fluid Power & Mechatron Syst, Hangzhou 310027, Peoples R China
基金
中国国家自然科学基金;
关键词
Hypoxia; PD-1; Tumor microenvironment; Pancreatic ductal adenocarcinoma; Oxygen microcapsules; PHOTODYNAMIC THERAPY; CANCER; CELLS; MICROENVIRONMENT; IMMUNOTHERAPY; NANOPARTICLES;
D O I
10.1016/j.bioactmat.2022.05.022
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
Rationale: Hypoxia in tumor microenvironment (TME) represents an obstacle to the efficacy of immunotherapy for pancreatic ductal adenocarcinoma (PDAC) through several aspects such as increasing the expression of immune checkpoints or promoting fibrosis. Reversing hypoxic TME is a potential strategy to improve the validity of immune checkpoint blockade (ICB). Methods: Here, we synthesized polydopamine-nanoparticle-stabilized oxygen microcapsules with excellent stabilization, bioavailability, and biocompatibility for direct oxygen delivery into tumor sites by interfacial polymerization. Results: We observed oxygen microcapsules enhanced the oxygen concentration in the hypoxia environment and maintained the oxygen concentration for a long period both in vitro and in vivo. We found that oxygen micro capsules could significantly improve the efficiency of ICB against PDAC in vivo. Mechanismly, combined treatments using oxygen microcapsules and ICB could reduce the infiltration of tumor-associated macrophages (TAMs) and polarized pro-tumor M2 macrophages into anti-tumor M1 macrophages. In addition, combined treatments could elevate the proportion of T helper subtype 1 cells (Th1 cells) and cytotoxic T lymphocytes cells (CTLs) to mediate anti-tumor immune response in TME. Conclusion: In summary, this pre-clinical study indicated that reversing hypoxia in TME by using oxygen microcapsules was an effective strategy to improve the performances of ICB on PDAC, which holds great potential for treating PDAC in the future.
引用
收藏
页码:259 / 270
页数:12
相关论文
共 50 条
  • [31] Galectin-1 in Pancreatic Ductal Adenocarcinoma: Bridging Tumor Biology, Immune Evasion, and Therapeutic Opportunities
    Bogut, Ana
    Stojanovic, Bojan
    Jovanovic, Marina
    Dimitrijevic Stojanovic, Milica
    Gajovic, Nevena
    Stojanovic, Bojana S.
    Balovic, Goran
    Jovanovic, Milan
    Lazovic, Aleksandar
    Mirovic, Milos
    Jurisevic, Milena
    Jovanovic, Ivan
    Mladenovic, Violeta
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (21)
  • [32] The immune escape signature predicts the prognosis and immunotherapy sensitivity for pancreatic ductal adenocarcinoma
    Lu, Hao
    Zheng, Li-Yan
    Wu, Ling-Yan
    Chen, Jun
    Xu, Na
    Mi, Sui-Cai
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [33] Comprehensive analysis of prognostic immune-related genes associated with the tumor microenvironment of pancreatic ductal adenocarcinoma
    Yan, Shibai
    Fang, Juntao
    Zhu, Yuanqiang
    Xie, Yong
    Fang, Feng
    ONCOLOGY LETTERS, 2020, 20 (06)
  • [34] Immune therapies in pancreatic ductal adenocarcinoma: Where are we now?
    Marc Hilmi
    Laurent Bartholin
    Cindy Neuzillet
    World Journal of Gastroenterology, 2018, (20) : 2137 - 2151
  • [35] Immune therapies in pancreatic ductal adenocarcinoma: Where are we now?
    Hilmi, Marc
    Bartholin, Laurent
    Neuzillet, Cindy
    WORLD JOURNAL OF GASTROENTEROLOGY, 2018, 24 (20) : 2137 - 2151
  • [36] Combined Blockade of MEK and CDK4/6 Pathways Induces Senescence to Improve Survival in Pancreatic Ductal Adenocarcinoma
    Willobee, Brent A.
    Gaidarski, Alexander A.
    Dosch, Austin R.
    Castellanos, Jason A.
    Dai, Xizi
    Mehra, Siddharth
    Messaggio, Fanuel
    Srinivasan, Supriya
    VanSaun, Michael N.
    Nagathihalli, Nagaraj S.
    Merchant, Nipun B.
    MOLECULAR CANCER THERAPEUTICS, 2021, 20 (07) : 1246 - 1256
  • [37] Comparative immune profiling of pancreatic ductal adenocarcinoma progression among South African patients
    Elebo, Nnenna
    Abdel-Shafy, Ebtesam A.
    Omoshoro-Jones, Jones A. O.
    Nsingwane, Zanele
    Hussein, Ahmed A. A.
    Smith, Martin
    Candy, Geoffrey
    Cacciatore, Stefano
    Fru, Pascaline
    Nweke, Ekene Emmanuel
    BMC CANCER, 2024, 24 (01)
  • [38] A Comparison of Spatial and Phenotypic Immune Profiles of Pancreatic Ductal Adenocarcinoma and Its Precursor Lesions
    Enzler, Thomas
    Shi, Jiaqi
    McGue, Jake
    Griffith, Brian D.
    Sun, Lei
    Sahai, Vaibhav
    Nathan, Hari
    Frankel, Timothy L.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (05)
  • [39] The Effects of Treatment on Peripheral Blood Immune Cell Profile in Pancreatic Ductal Adenocarcinoma (PDAC)
    Tulyte, Skaiste
    Characiejus, Dainius
    Matuzeviciene, Reda
    Janiulioniene, Ausra
    Radzevicius, Mantas
    Zvirblis, Tadas
    Sileikis, Audrius
    ANTICANCER RESEARCH, 2022, 42 (06) : 3067 - 3073
  • [40] KRAS Mutation Dictates the Cancer Immune Environment in Pancreatic Ductal Adenocarcinoma and Other Adenocarcinomas
    Gu, Meichen
    Gao, Yanli
    Chang, Pengyu
    CANCERS, 2021, 13 (10)